TREATMENT OUTCOMES FOR CHILDREN WITH ANXIETY DISORDERS

本申请建议莫伊拉·a·林恩，医学博士获得宾夕法尼亚大学指导病人导向研究职业发展奖。这个项目的目的包括：1)支持我发展成为一名独立的研究科学家；2)支持和加强我作为儿童和青少年焦虑症研究者的发展；3)发展自己的能力，运用临床经验设计和执行一项方案，以回答提出的研究问题；4)根据在资助期间进行的研究，为准备RO1资助申请提供基础工作。这些目标将通过一个结构化的四部分计划来实现：1)在Brian Strom博士的指导下完成临床流行病学硕士学位，这是一个正式的学术课程和教程，以提高我的研究技能；2)获得资深科学家的研究培训和指导，他将作为我的赞助人（Karl ricels，医学博士）以及共同赞助人（Edna Foa，博士）和合作者（Elizabeth Weller，医学博士，Irwin Lucki，博士，John March，医学博士，公共卫生学博士，Brian Strom，医学博士，公共卫生学博士和Philip C. Kendall，博士，ABPP）；3)参加情绪和焦虑障碍科正在进行的儿童和成人焦虑和抑郁的精神药理学试验；4)设计并执行原创性临床研究治疗方案。符合广泛性焦虑障碍、分离性焦虑障碍或无焦虑症诊断的8 - 12岁11个月儿童将进入一项随机、双盲、安慰剂对照试验，以评估每天50mg舍曲林（Pt N = 60）的安全性和有效性。我也会评估父母精神病理的存在对孩子的损伤程度，紊乱的发生以及对药物治疗的反应的调节作用。这些家庭将被跟踪一年，为进一步的研究收集资料。

This application proposes Moira A. Rynn, M.D. for a Mentored Patient-Oriented Research Career Development Award at the University of Pennsylvania. The aims of this program include: 1) to support my development into an independent research scientist; 2) to support and enhance my development as an investigator in anxiety disorders in children and adolescents; 3) to develop my ability to use my clinical experience to design and execute a protocol that will answer a proposed research question; and 4) to provide the groundwork for the preparation of an RO1 grant application based on the research performed during the award period. These aims will be accomplished through a structured four-part plan: 1) to complete a Master's of Science of Clinical Epidemiology, a program of formal academic courses and tutorials to enhance my research skills, under the supervision of Dr. Brian Strom; 2) to obtain research training and mentoring by a senior scientist who will serve as my sponsor (Karl Rickels, M.D.) as well as by a co-sponsor (Edna Foa, Ph.D) and collaborators (Elizabeth Weller, M.D., Irwin Lucki, Ph.D., John March, M.D., M.P.H., Brian Strom, M.D., M.P.H., and Philip C. Kendall, Ph.D., ABPP); 3) to participate in several ongoing psychopharmacological trials for anxiety and depression in both children and adults in the Mood and Anxiety Disorders Section; and 4) to design and execute an original clinical research treatment protocol. Children aged 8 to 12 years and 11 months who meet the diagnosis of generalized anxiety disorder, separation anxiety disorder, or anxiety disorder nos will enter a randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of 50 mg sertraline per day (Pt N = 60). I also will evaluate the moderating effect the presence of parental psychopathology has on the child's level of impairment, onset of disorder and response to medication treatment. Families will be followed for one year to collect for further research.